Evaluation of Xpert ® BCR‐ABL Ultra for the confirmation of BCR‐ABL1 international scale conversion factors for the molecular monitoring of chronic myeloid leukaemia

2020 ◽  
Author(s):  
Katherine M. Dominy ◽  
Iris M. Simon ◽  
Jamshid Sorouri‐Khorashad
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Molecular Monitoring ◽  
Conversion Factors ◽  
International Scale

Cepheid xpert monitor platform for the confirmation of BCR-ABL1 IS conversion factors for the molecular monitoring of chronic myeloid leukaemia

2016 ◽  
Vol 49 ◽  
pp. 47-50 ◽  
Author(s):  
Gareth Gerrard ◽  
Hui En Foong ◽  
Katherine Mudge ◽  
Mary Alikian ◽  
Jane F. Apperley ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Molecular Monitoring ◽  
Conversion Factors

scholarly journals Present and future of molecular monitoring in chronic myeloid leukaemia

2016 ◽  
Vol 173 (3) ◽  
pp. 337-349 ◽  
Author(s):  
Simona Soverini ◽  
Caterina De Benedittis ◽  
Manuela Mancini ◽  
Giovanni Martinelli
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Molecular Monitoring

scholarly journals A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at Time of SARS-CoV-2 Pandemic

Diagnostics ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1502
Author(s):  
Stefania Stella ◽  
Silvia Rita Vitale ◽  
Michele Massimino ◽  
Adriana Puma ◽  
Cristina Tomarchio ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Kinase Inhibitors ◽  
Quantitative Polymerase Chain Reaction ◽  
White Blood Cells ◽  
Rna Isolation ◽  
Molecular Testing ◽  
Molecular Response ◽  
Molecular Monitoring ◽  
Semiautomatic System

Molecular testing of the BCR-ABL1 transcript via real-time quantitative-polymerase-chain-reaction is the most sensitive approach for monitoring the response to tyrosine-kinase-inhibitors therapy in chronic myeloid leukaemia (CML) patients. Each stage of the molecular procedure has been standardized and optimized, including the total white blood cells (WBCs) and RNA isolation methods. Here, we compare the performance of our current manual protocol to a newly semiautomatic method based on the Biomek i-5 Automated Workstations integrated with the CytoFLEX Flow Cytometer, followed by the automatic QIAsymphony system to facilitate high-throughput processing samples and reduce the hands-on time and the risk associated with SARS-CoV-2. The recovery efficiency was investigated in blood samples from 100 adults with CML. We observe a 100% of concordance between the two methods, with similar total WBCs isolated (median 1.137 × 106 for manual method vs. 1.076 × 106 for semiautomatic system) and a comparable quality and quantity of RNA extracted (median 103 ng/μL with manual isolation kit vs. 99.95 ng/μL with the QIAsymphony system). Moreover, by stratifying patients according to their BCR-ABL1 transcript levels, we obtained similar BCR-ABL1/ABL1IS values and ABL1 copies, and matched samples were assigned to the same group of molecular response. We conclude that this newly semiautomatic workflow has a performance comparable to our more laborious standard manual, which can be replaced, particularly when specimens from patients with suspected or confirmed SARS-CoV-2 infection need to be processed.

Cytogenetic and Molecular Monitoring of Residual Disease in Chronic Myeloid Leukaemia

2002 ◽  
Vol 107 (2) ◽  
pp. 64-75 ◽  
Author(s):  
Jaspal Kaeda ◽  
Andrew Chase ◽  
John M. Goldman
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Residual Disease ◽  
Molecular Monitoring
Sign in / Sign up

Export Citation Format

Share Document